Or the chronic wound study comes back with positive results that allow for reimbursement by insurance.
That's another $600m market opened up right there (according to PNV's estimates, I'd argue that's an underestimate).
The study is due to be finished this month. I don't know how quickly things get approved for reimbursement in the states but that market may not be far off.
Ann: FY21 BTM Revenue Results, page-164
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.04 |
Change
-0.030(1.45%) |
Mkt cap ! $1.409B | |||
| Open | High | Low | Value | Volume |
| $2.09 | $2.11 | $2.03 | $1.727M | 838.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 299194 | $2.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.04 | 1559 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PNV (ASX) Chart |